SNCA and Parkinson disease: When tested in an A53T alpha-synuclein mouse model, the increase in GCase levels reduced alpha-synuclein levels, demonstrating the relationship between alpha-synuclein and GCase activity and suggesting that this approach may also be beneficial for PD without GBA1 mutations (Sardi et al., 2013).